US · IDYA · BIOTECHNOLOGY
IDEAYA Biosciences, Inc. (IDYA) intrinsic value and stock valuation
$25.56as of 2026-11-21 · Mkt cap 3.52B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
IDEAYA Biosciences, Inc. DCF and intrinsic value
InvestorsCraft values IDYA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IDYA’s statements →
IDEAYA Biosciences, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cogent Biosciences, Inc. (COGT) $26.72
- Scholar Rock Holding Corporation (SRRK) $48.13
- Kiniksa Pharmaceuticals International, plc (KNSA) $93.90
- Adaptive Biotechnologies Corporation (ADPT) $27.93
- Legend Biotech Corporation (LEGN) $15.25
- Beam Therapeutics Inc. (BEAM) $20.90
- Zai Lab Limited (ZLAB) $21.03
- Mineralys Therapeutics, Inc. (MLYS) $13.66
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $218.7M | $7M | $23.4M | $50.9M | $27.9M |
| Operating income | -$-159.31M | -$-326.98M | -$-134.43M | -$-62.5M | -$-50.27M |
| Net income | -$-113.7M | -$-274.48M | -$-112.96M | -$-58.66M | -$-49.76M |
| EPSd | -$-1.28M | -$-3.36M | -$-1.96M | -$-1.42M | -$-1.41M |
| Operating cash flow | -$-71.1M | -$-247.58M | -$-115.22M | -$-87.17M | -$-55.78M |
| Capital expenditure | -$-2.37M | -$-3.86M | -$-2.37M | -$-3.44M | -$-2.64M |
| Free cash flow | -$-73.47M | -$-251.44M | -$-117.59M | -$-90.62M | -$-58.42M |
| Total assets | $1.11B | $1.12B | $649.3M | $388M | $381.4M |
| Total debt | $27.9M | $19.2M | $2.87M | $3.48M | $5.18M |
| Net debt | -$-84.91M | -$-65.21M | -$-154.15M | -$-65.15M | -$-86.86M |
| Total equity | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M |
| Cash and short-term investments | $639.4M | $676.3M | $525.1M | $364.8M | $246.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $218.7M | $7M | $23.4M | $50.9M | $27.9M |
| Cost of revenue | $4.59M | $3.83M | $4.01M | $2.1M | $1.73M |
| Gross profit | $214.1M | $3.17M | $19.4M | $48.8M | $26.2M |
| Research and development expenses | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M |
| Selling, general and administrative expenses | $63.3M | $35.5M | $24.3M | $21.8M | $18.3M |
| Other expenses | -$-4.59M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $373.4M | $330.1M | $153.8M | $111.3M | $76.5M |
| Cost and expenses | $378M | $334M | $157.8M | $113.4M | $78.2M |
| Interest income | $45.6M | $52.5M | $21.5M | $3.85M | $510K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $4.59M | $3.83M | $4.01M | $2.1M | $1.73M |
| Ebitda | -$-109.11M | -$-270.64M | -$-108.95M | -$-56.55M | -$-48.04M |
| Operating income | -$-159.31M | -$-326.98M | -$-134.43M | -$-62.5M | -$-50.27M |
| Total other income/expenses, net | $45.6M | $52.5M | $21.5M | $3.85M | $510K |
| Income before tax | -$-113.7M | -$-274.48M | -$-112.96M | -$-58.66M | -$-49.76M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-113.7M | -$-274.48M | -$-112.96M | -$-58.66M | -$-49.76M |
| Weighted average shares outstanding | $88.5M | $81.7M | $57.5M | $41.4M | $35.3M |
| Weighted average diluted shares outstanding | $88.5M | $81.7M | $57.5M | $41.4M | $35.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $639.4M | $676.3M | $525.1M | $364.8M | $246.8M |
| Net receivables | $5.97M | $0.00 | $20K | $210K | $1.1M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $666.7M | $689.7M | $532.6M | $370.5M | $251M |
| Property, plant and equipment, net | $31.3M | $27.7M | $8.41M | $8.99M | $8.66M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $410.3M | $405.8M | $107.5M | $8.32M | $121.3M |
| Total non-current assets | $442.6M | $434.4M | $116.7M | $17.5M | $130.4M |
| Total assets | $1.11B | $1.12B | $649.3M | $388M | $381.4M |
| Accounts payable | $17.6M | $15.4M | $6.6M | $4.28M | $2.1M |
| Short-term debt | $340K | $300K | $1.75M | $1.87M | $1.7M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $8.57M | $29M |
| Total current liabilities | $58.8M | $46.1M | $27.1M | $31.7M | $45.2M |
| Long-term debt | $27.6M | $18.9M | $1.12M | $1.61M | $3.48M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $5.18M | $31.2M |
| Total non-current liabilities | $27.6M | $18.9M | $1.12M | $6.8M | $34.7M |
| Capital lease obligations | $0.00 | $19.2M | $2.87M | $3.48M | $5.18M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M |
| Common stock | $10K | $10K | $10K | $10K | $0.00 |
| Retained earnings | -$-736.54M | -$-622.84M | -$-348.36M | -$-235.4M | -$-176.75M |
| Accumulated other comprehensive income (loss) | $2.27M | $810K | $560K | -$-2.87M | -$-710K |
| Total equity | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M |
| Total investments | $936.9M | $997.8M | $475.6M | $304.5M | $276M |
| Total debt | $27.9M | $19.2M | $2.87M | $3.48M | $5.18M |
| Net debt | -$-84.91M | -$-65.21M | -$-154.15M | -$-65.15M | -$-86.86M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-113.7M | -$-274.48M | -$-112.96M | -$-58.66M | -$-49.76M |
| Depreciation and amortization | $4.59M | $3.83M | $4.01M | $2.1M | $1.73M |
| Stock-based compensation | $46.1M | $34.8M | $18.5M | $11.6M | $8.24M |
| Change in working capital | $1.87M | $11.6M | -$-13.21M | -$-41.55M | -$-17.81M |
| Accounts receivable | $0.00 | $10K | $190K | $890K | $770K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $3.79M |
| Accounts payable | $2.7M | $8.28M | $2.63M | $1.86M | $1.17M |
| Net cash provided by operating activities | -$-71.1M | -$-247.58M | -$-115.22M | -$-87.17M | -$-55.78M |
| Investments in property, plant and equipment | -$-2.37M | -$-3.86M | -$-2.37M | -$-3.44M | -$-2.64M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $33.4M | $67M |
| Net cash used for investing activities | $70M | -$-502.56M | -$-158.46M | -$-33.4M | -$-69.67M |
| Common stock issued | $29.8M | $654.2M | $309.8M | $95M | $143.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $29.8M | $677.6M | $362.7M | $97.2M | $145.5M |
| Net change in cash | $28.5M | -$-72.59M | $89M | -$-23.41M | $20M |
| Cash at end of period | $112.8M | $85.2M | $157.8M | $68.7M | $92.2M |
| Operating cash flow | -$-71.1M | -$-247.58M | -$-115.22M | -$-87.17M | -$-55.78M |
| Capital expenditure | -$-2.37M | -$-3.86M | -$-2.37M | -$-3.44M | -$-2.64M |
| Free cash flow | -$-73.47M | -$-251.44M | -$-117.59M | -$-90.62M | -$-58.42M |
Line items
Line items
Line items
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
- CEO
- Yujiro S. Hata
- Employees
- 145
- Beta
- -0.09
Explore
Frequently asked questions
What is the intrinsic value of IDEAYA Biosciences, Inc. (IDYA)?
IDEAYA Biosciences, Inc. (IDYA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IDYA undervalued?
IDYA trades at a price of $25.56 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.